Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies

Abstract

Background

Individuals with recent HCV infection may benefit from shortened duration therapy. These studies evaluated the efficacy and safety of response-guided regimens with pegylated interferon-α2a and ribavirin for people with recent HCV infection.

Methods

Participants with recent hepatitis C (duration of infection ≤18 months) enrolled in the ATAHC II (pegylated interferon-α2a + ribavirin) and DARE-C I (pegylated interferon-α2a, ribavirin and telaprevir) studies were included for analysis. Treatment duration was response-guided (ATAHC II: 8, 16, 24 or 48 weeks; DARE-C I: 8, 12 or 24 weeks) and dependent on time to first undetectable HCV RNA using Roche Taqman HCV RNA testing. The primary efficacy end point was sustained virological response at 12 weeks (SVR12) by intention-to-treat. Logistic regression analyses were used to identify predictors of SVR.

Results

A total of 82 participants (62% HIV-positive) were enrolled in ATAHC II (treated, n=52) and 14 (79% HIV-positive) in DARE-C I. The predominant modes of HCV acquisition were injecting drug use (ATAHC II 55%, DARE-C I 36%) and sexual intercourse with a partner of the same sex (ATAHC II 39%, DARE-C I 64%). SVR12 was 71% in both ATAHC II (37/52) and DARE-C I (10/14) with 56% in ATAHC II receiving shortened therapy (8 or 16 weeks). SVR was associated with a rapid virological response (odds ratio 10.80; P=0.001).

Conclusions

The majority of participants were able to receive short duration response-guided therapy with pegylated interferon-α2a and ribavirin. Response-guided therapy for recent hepatitis C infection could be considered in the absence of available interferon-free therapies. ClinicalTrials.gov registry (ATAHC II: NCT01336010; DARE-C I: NCT01743521).

References

Martinello

, Matthews

G.V.

Enhancing the detection and management of acute hepatitis C virus infection.

Int J Drug Policy 2015; 26: 899–910.

European Association for the Study of the Liver.

EASL Recommendations on Treatment of Hepatitis C 2015.

J Hepatol 2015; 63: 199–236.

AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C, 2015. (Accessed 8 November 2015.) Available from http://www.hcvguidelines.org.

Dore

G.J.

, Feld

J.J.

Hepatitis C virus therapeutic development: in pursuit of ‘perfectovir’.

Clin Infect Dis 2015; 60: 1829–1836.

Nomura

, Sou

, Tanimoto

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial.

Hepatology 2004; 39: 1213–1219.

De Rosa

F.G.

, Bargiacchi

, Audagnotto

Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.

J Antimicrob Chemother 2006; 57: 360–363.

Kamal

S.M.

, Moustafa

K.N.

, Chen

Duration of peginterferon therapy in acute hepatitis C: a randomized trial.

Hepatology 2006; 43: 923–931.

Calleri

, Cariti

, Gaiottino

A short course of pegylated interferon-alpha in acute HCV hepatitis.

J Viral Hepat 2007; 14: 116–121.

Santantonio

, Fasano

, Sagnelli

Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin.

Hepatology 2014; 59: 2101–2109.

10.

Dore

G.J.

, Hellard

, Matthews

G.V.

Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.

Gastroenterology 2010; 138: 123–135.

11.

AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C, 2014. (Accessed 8 October 2014.) Available from http://www.hcvguidelines.org.

12.

Hajarizadeh

, Grebely

, Dore

G.J.

Case definitions for acute hepatitis C virus infection: a systematic review.

J Hepatol 2012; 57: 1349–1360.

13.

Jacka

, Applegate

, Krajden

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada.

Hepatology 2014; 60: 1571–1580.

14.

Lamoury

F.M.

, Jacka

, Bartlett

The influence of hepatitis C virus genetic region on phylogenetic clustering analysis.

PLoS ONE 2015; 10: e0131437.

15.

Wyles

D.L.

, Ruane

P.J.

, Sulkowski

M.S.

Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1.

N Eng J Med 2015; 373: 714–725.

16.

Naggie

, Cooper

, Saag

Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1.

N Eng J Med 2015; 373: 705–713.

17.

Dore

G.J.

, Conway

, Luo

Randomized trials of ombitasvir/paritaprevir/r+dasabuvir+/-ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV.

J Hepatol 2015; 62 Suppl 2: S656–S657.

18.

Sulkowski

, Hezode

, Gerstoft

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label Phase 2 trial.

Lancet 2015; 385: 1087–1097.

19.

Sulkowski

M.S.

, Eron

J.J.

, Wyles

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial.

JAMA 2015; 313: 1223–1231.

20.

Feld

J.J.

, Jacobson

I.M.

, Hezode

Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.

N Eng J Med 2015; 373: 2599–2607.

21.

Lawitz

, Poordad

F.F.

, Pang

P.S.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, Phase 2 trial.

Lancet 2014; 383: 515–523.

22.

Barua

, Greenwald

, Grebely

, Dore

G.J.

, Swan

, Taylor

L.E.

Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States.

Ann Intern Med 2015; 163: 215–223.

23.

Fierer

D.S.

, Dieterich

D.T.

, Mullen

M.P.

Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

Clin Infect Dis 2014; 58: 873–879.

24.

Jacobson

I.M.

, McHutchison

J.G.

, Dusheiko

Telaprevir for previously untreated chronic hepatitis C virus infection.

N Engl J Med 2011; 364: 2405–2416.

25.

Montes

, Nelson

, Girard

P.M.

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis.

J Int AIDS Soc 2014; 17 Suppl 3: 19626.

26.

Matthews

G.V.

, Pham

S.T.

, Hellard

Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.

Clin Infect Dis 2011; 52: 803–811.

27.

Wandeler

, Gsponer

, Bregenzer

Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.

Clin Infect Dis 2012; 55: 1408–1416.

28.

Centers for Disease Control and Prevention.

Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men–New York City, 2005-2010.

MMWR Morb Mortal Wkly Rep 2011; 60: 945–950.

29.

Schmidt

A.J.

, Rockstroh

J.K.

, Vogel

Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany–a case-control study.

PLoS ONE 2011; 6: e17781.

30.

van de Laar

, Pybus

, Bruisten

Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.

Gastroenterology 2009; 136: 1609–1617.

31.

Gamage

D.G.

, Read

T.R.

, Bradshaw

C.S.

Incidence of hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study.

BMC Infect Dis 2011; 11: 39.

32.

Danta

, Brown

, Bhagani

Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.

AIDS 2007; 21: 983–991.

33.

Simmons

, Saleem

, Hill

Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis.

Clin Inf Dis 2016; 62: 683–694.

34.

Lambers

F.A.

, Prins

, Thomas

Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.

AIDS 2011; 25: F21–F27.

35.

Ingiliz

, Krznaric

, Stellbrink

H.J.

Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance.

HIV Med 2014; 15: 355–361.

36.

Martin

T.C.

, Martin

N.K.

, Hickman

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

AIDS 2013; 27: 2551–2557.

37.

Dore

, Altice

, Litwin

A.H.

C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy.

Hepatology 2015; 62 Suppl: 227A.

38.

Doyle

J.S.

, Shaw

, Dore

G.J.

Low rates of re-infection and reduced injecting long-term following recently acquired HCV in the Australian trial of acute hepatitis C: the ATAHC recall study. AIDS. 20–25 July 2014, Melbourne, Australia. Poster discussion TUPDB0103.

39.

Aspinall

E.J.

, Corson

, Doyle

J.S.

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

Clin Infect Dis 2013; 57 Suppl 2: S80–S89.

40.

Dore

G.J.

, Feld

J.J.

Hepatitis C virus therapeutic development: in pursuit of perfectovir.

Clin Infect Dis 2015; 60: 1829–1836.